Impact of Endogenous E2 on SSI and GH Rebound

NCT02026973 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Normal Healthy Volunteers

Interventions

DRUG: Fulvestrant
DRUG: Anastrozole
DRUG: Placebo
DRUG: Somatostatin

Sponsor

Mayo Clinic